CA2851387A1 - Cysteamine and/or cystamine for treating ischemic injury - Google Patents

Cysteamine and/or cystamine for treating ischemic injury Download PDF

Info

Publication number
CA2851387A1
CA2851387A1 CA2851387A CA2851387A CA2851387A1 CA 2851387 A1 CA2851387 A1 CA 2851387A1 CA 2851387 A CA2851387 A CA 2851387A CA 2851387 A CA2851387 A CA 2851387A CA 2851387 A1 CA2851387 A1 CA 2851387A1
Authority
CA
Canada
Prior art keywords
cysteamine
cystamine
derivative
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2851387A
Other languages
English (en)
French (fr)
Inventor
Ranjan Dohil
Susan A. Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2851387A1 publication Critical patent/CA2851387A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2851387A 2011-11-22 2012-11-21 Cysteamine and/or cystamine for treating ischemic injury Abandoned CA2851387A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563034P 2011-11-22 2011-11-22
US61/563,034 2011-11-22
PCT/US2012/066288 WO2013078335A1 (en) 2011-11-22 2012-11-21 Cysteamine and/or cystamine for treating ischemic injury

Publications (1)

Publication Number Publication Date
CA2851387A1 true CA2851387A1 (en) 2013-05-30

Family

ID=47297472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2851387A Abandoned CA2851387A1 (en) 2011-11-22 2012-11-21 Cysteamine and/or cystamine for treating ischemic injury

Country Status (16)

Country Link
US (1) US20140322315A1 (enExample)
EP (1) EP2782564B1 (enExample)
JP (1) JP6411215B2 (enExample)
KR (1) KR20140097132A (enExample)
CN (2) CN108042517A (enExample)
AU (1) AU2012340670B2 (enExample)
BR (1) BR112014012167A2 (enExample)
CA (1) CA2851387A1 (enExample)
HK (1) HK1202440A1 (enExample)
IL (1) IL232608A0 (enExample)
MX (1) MX2014004469A (enExample)
MY (1) MY165953A (enExample)
RU (1) RU2638807C2 (enExample)
SG (2) SG11201402472QA (enExample)
WO (1) WO2013078335A1 (enExample)
ZA (1) ZA201402290B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
ES2770113T3 (es) * 2015-07-02 2020-06-30 Horizon Orphan Llc Análogos de la cisteamina resistentes a la ADO y sus usos
CN106591461A (zh) * 2016-12-29 2017-04-26 天津协和华美医学诊断技术有限公司 一种检测遗传性易栓症相关基因群的检测试剂盒
CN110392568A (zh) * 2017-01-19 2019-10-29 耳科制药公司 N-乙酰半胱氨酸的制剂及其用途
EP3573994A4 (en) 2017-01-25 2020-11-11 Adare Pharmaceuticals, Inc. MEDICINES OF CYSTEAMINE
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN113484453B (zh) * 2021-07-07 2022-08-09 天津中医药大学 一种缺血性脑卒中预警方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
FR2573077B1 (fr) * 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
EP0306937A3 (en) * 1987-09-08 1990-07-25 The Green Cross Corporation Platelet agglutination-inhibiting agent
JPH02243619A (ja) * 1989-03-15 1990-09-27 Green Cross Corp:The 抗血小板凝集剤
WO1990014087A1 (en) 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (enExample) 1993-09-02 1996-07-21 Hoffmann La Roche
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1997023202A1 (en) 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat
PL340080A1 (en) 1997-10-24 2001-01-15 Warner Lambert Co Method of treating disease-related or post-drug dyskinesias
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
WO2000025109A1 (en) 1998-10-28 2000-05-04 Scofield Dillon F Electrodynamic particle size analyzer
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
CA2386441A1 (en) 1999-10-29 2001-05-03 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
RU2367423C2 (ru) * 2003-12-19 2009-09-20 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Композиции и способы для лечения диабета
RU2387445C2 (ru) * 2004-05-03 2010-04-27 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Материалы и способы модуляции метаболизма
JP5583022B2 (ja) * 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
RU2428192C1 (ru) * 2010-06-10 2011-09-10 Войсковая Часть 41598 Радиозащитное средство

Also Published As

Publication number Publication date
AU2012340670A1 (en) 2014-04-17
SG10201800159QA (en) 2018-02-27
RU2638807C2 (ru) 2017-12-15
EP2782564A1 (en) 2014-10-01
BR112014012167A2 (pt) 2017-05-30
SG11201402472QA (en) 2014-06-27
WO2013078335A1 (en) 2013-05-30
JP6411215B2 (ja) 2018-10-24
MX2014004469A (es) 2014-08-01
AU2012340670B2 (en) 2016-12-22
KR20140097132A (ko) 2014-08-06
MY165953A (en) 2018-05-18
ZA201402290B (en) 2017-06-28
JP2014533701A (ja) 2014-12-15
US20140322315A1 (en) 2014-10-30
CN103974698A (zh) 2014-08-06
EP2782564B1 (en) 2019-01-09
IL232608A0 (en) 2014-06-30
RU2014125282A (ru) 2015-12-27
HK1202440A1 (zh) 2015-10-02
CN108042517A (zh) 2018-05-18

Similar Documents

Publication Publication Date Title
AU2012340670B2 (en) Cysteamine and/or cystamine for treating ischemic injury
JP2021001193A (ja) 重水素化又は非重水素化分子及び医薬製剤
US20210100827A1 (en) Combined administration of cysteine-aspartic protease inhibitors with p2y12 receptor antagonists protects the heart against myocardial infarction
TWI331920B (en) Unit dosage form for relieving or treating constipation in human patients
JP2020525552A (ja) ポリペプチドの薬学的に許容される塩およびその使用
MX2014003256A (es) Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesion neuronal.
CN1997358A (zh) 贝壳杉烷类化合物在制备药物中的应用
JPH115738A (ja) 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
CN1980673B (zh) 预防血栓栓塞性疾病的方法
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
CN117257803A (zh) 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用
EP1292292B1 (en) Method for treating congestive heart failure
US20250235502A1 (en) Cardio-protective effect of vasoconstriction-inhibiting factor (vif)
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
JP2834507B2 (ja) 芳香族誘導体を活性成分とする疾患治療剤
JP2654518B2 (ja) 肝細胞増殖促進剤
JP2024510653A (ja) 急性虚血性脳卒中を治療するｄｃ００９
JP2024503377A (ja) バダデュスタットを使用した治療方法
HK40097424A (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途
WO2025193765A1 (en) Therapeutic regimens and methods for reducing body weight and/or serum lipids using a glp-1r and gcgr agonist
WO2023151638A1 (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途
WO2008068577A2 (en) Pharmaceutical compositions
EP2687264A1 (en) Macrophage Activating Factor for treatment of endometriosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171109

FZDE Discontinued

Effective date: 20191121